Cue Biopharma to Discuss CUE-401 Advances at Cantor Global Healthcare Conference

Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Cantor Global Healthcare Conference to discuss updates on its Immuno-STAT platform and lead autoimmune asset CUE-401. The presentation will be on September 5, 2025, from 8:00 a.m. to 8:30 a.m. ET, and will be webcast live and archived on Cue Biopharma's website.

Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Cantor Global Healthcare Conference to discuss updates on its Immuno-STAT platform and lead autoimmune asset CUE-401. The presentation, scheduled for September 5, 2025, from 8:00 a.m. to 8:30 a.m. ET, will be webcast live and archived on Cue Biopharma's website [1].

The fireside chat will provide investors and financial professionals with an opportunity to gain insights into Cue Biopharma's latest advancements and strategic initiatives. The Immuno-STAT platform is a key focus area for the company, with a strong emphasis on developing innovative therapies for autoimmune diseases. CUE-401, a lead asset within this platform, has shown promising clinical results, with the company reporting a 50% response rate in its Phase 1b trial for HPV+ head and neck cancer [2].

The presentation comes at a critical juncture for Cue Biopharma. The company reported a 11.1% year-over-year revenue increase to $2.95 million and a 16.6% reduction in net loss to $8.48 million in Q2 2025, driven by a $12 million partnership with Boehringer Ingelheim for the development of CUE-501 [3]. While these results indicate progress, the company's financial trajectory remains precarious, with an annualized cash burn rate of $30 million and a cash runway of 3-4 quarters [3]. The fireside chat will likely address these challenges and provide updates on the company's financial health and strategic partnerships.

Investors are encouraged to tune in to the webcast to gain a better understanding of Cue Biopharma's progress and future prospects. The company's ability to leverage its partnerships, advance its pipeline, and extend its cash runway will be key determinants of its long-term viability. For now, the stock remains a high-risk, high-reward proposition, suitable for investors with a strong risk tolerance and a long-term horizon [3].

References:
[1] Cue Biopharma, "Fireside Chat at Cantor Global Healthcare Conference," https://www.cuebiopharma.com/events
[2] Cue Biopharma, "Clinical Progress Update for CUE-101," https://www.cuebiopharma.com/news/cue-101-clinical-progress
[3] AInvest, "Cue Biopharma Q2 2025 Earnings Beat Revenue Growth Glimpse Sustainable Turnaround Potential," https://www.ainvest.com/news/cue-biopharma-q2-2025-earnings-beat-revenue-growth-glimpse-sustainable-turnaround-potential-2508/